You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma

    SBC: LEUKOGENE THERAPEUTICS INC            Topic: 102

    Project Summary Abstract Multiple MyelomaMMis the second most common form of blood cancer and remains an incurable and deadly diseaseProteasome inhibitorPItherapy is a cornerstone in the treatment of MMbut resistance to this class of agent is an emerging challenge in the clinicNew therapeutic approaches that specifically target resistance are needed to maximize responses and ultimately produce cur ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Novel therapeutic approach in treatment of glioblastoma using sustained delivery of Connxin43 carboxy-terminal peptide encapsulated in biodegradable nanoparticles in combination with temozolomide

    SBC: FirstString Research, Inc            Topic: 102

    PROJECT SUMMARY Glioblastoma (GBM) is an incurable cancer even with aggressive therapies such as surgical resection followed by radiotherapy and chemotherapy using temozolomide (TMZ). Efforts to improve surgical resection or the efficacy of irradiation are limited by the potential damage these interventions cause to the brain. In contrast, sensitizing GBM to TMZ is an appealing strategy because TM ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Administrative Supplement to Promote Diversity in Research and Development Small Businesses

    SBC: NEUROENE THERAPEUTICS INC            Topic: NINDS

    Abstract Neuroene Therapeutics is a biotech company established to develop and commercialize safe effective therapies for epilepsyinpeople develop epilepsy in their lifetimehowever the currently available anti epileptic drugsAEDshave several issues and liabilities that leave unmet market needssuch asnot controlling seizures forof patients with epilepsycurrent AEDs only treat the symptoms of epilep ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Development of a Low-Profile Dual Hormone Patch Pump with Novel Occlusion Sensor

    SBC: SFC FLUIDICS, INC.            Topic: 200

    Development of a Low Profile Dual Hormone Patch Pumpwith Novel Occlusion Sensor Project SummaryThe Specific Aim of this project is to develop a discretelow profiledual hormone drug delivery system using SFC Fluidicsenabling microfluidic technologiesA DualPumpwill be developed in which one proprietary ePumpbody will independently and accurately deliver both insulin and glucagon from two separate re ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Development of an Autism Spectrum Disorder Screening Test based upon Metabolic Profiling of Fresh Blood Samples

    SBC: CIRCA BIOSCIENCE LLC            Topic: 102

    Autism spectrum disorderASDis a neurodevelopmental disorder characterized by significant deficits in reciprocal social interactionsimpaired communication and restrictedrepetitive behaviorswith a prevalence ofinchildren in the USEarly intervention programs have been shown to be effective for improving IQlanguageand social skills for toddlers as young asmonths of ageDiagnosis of ASD is currently bas ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Nucleobase aminosugars with reduced ototoxicity

    SBC: NUBAD LLC            Topic: Y

    PROJECT SUMMARYAminoglycosides are one of the cheapest and well known antibiotics in clinical use for overyearsbut one of the major limitations in their use is their ototoxicityWe are developing fast and low cost methods to develop aminoglycosides with antiribosomal activities and reduced toxicityIn this projectwe will identify novel aminoglycoside antibacterialsthat show reduced ototoxicityComple ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Multicolor Photoacoustic Malaria Detector

    SBC: CytoAstra, LLC            Topic: NIAID

    Summary Malaria continues to be a global health prioritywith almost half of the world s populationbillionat risk and arounddeaths each yearOvertreatment is caused by lack of diagnosis and contributes to resistancea huge threat as illustrated by artemisinin resistance in Southeast AsiaLittle progress has been made in the novel methods to diagnose malarialet alone in reliably identifying asymptomati ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Emodin as a complementary dietary therapy to reduce toxicity of 5 fluorouracil

    SBC: AcePre, LLC            Topic: NCCIH

    PROJECT SUMMARYfluorouracilFUhas been the first choice chemotherapy drug for colorectal cancerCRCfor many yearshoweverits clinical utility remains hindered by hematopoietic and gastrointestinal toxicities resulting from its non selectivitySide effects include fatigueloss of appetiteand diarrhea among othersall of which can lead to reduced quality of lifeThe economic burden associated with chemothe ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  9. MPS I Skeletal Disease Therapy with Novel Lectin-delivered Replacement Enzyme

    SBC: BIOSTRATAGIES LC            Topic: NIAMS

    BioStrategies LC is developing the plant galactose binding lectinRTBas an enzyme carrier capable of expanding delivery of enzyme replacement therapiesERTstohardto treatorgans and tissues such as boneThe rare lysosomal disease mucopolysaccharidosis IMPS Iis a progressive multisystem disorderwhich presents with significant skeletal abnormalities that play a major role in patient disease progressionM ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Feasibility study of a nanostructural system for bone regeneration in preparation for dental implants

    SBC: NuShores Biosciences LLC            Topic: 100

    Project SummaryCurrent bone grafting techniques for functional rehabilitation with dental implants have limitationshighcostdifficulties with fixation and stabilizationinsufficient bone regenerationhigh morbidity using autogenous block grafts and prolonged healing of up tomonthsExisting synthetic bone fillers cannot match defect shape and volumeare weakly resorbedif at allare not easily and quickly ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government